Previous 10 | Next 10 |
DBV Technologies (NASDAQ:DBVT): Q2 GAAP EPS of -$0.56 beats by $0.01. Cash and Cash Equivalents as of June 30, 2021 were $125.5 million, compared to $196.4 million as of December 31, 2020 and $152.5 million as of March 31, 2021. Press Release For further details see: DBV Technologies EP...
Montrouge, France, August 2, 2021 DBV Technologies Reports Second Quarter 2021 Financial Results and Recent Business Developments Business Highlights : Viaskin Peanut US: DBV submitted the protocol for the 6-month adhesion and safety stu...
Montrouge, France, July 26, 2021 DBV Technologies to Report First Half 2021 Financial Results and Business Updates on August 2, 2021 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical compan...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ...
Montrouge, France, June 2, 2021 DBV Technologies to Present at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé...
Montrouge, France, May 19, 2021 DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and the A ppointment of Dr. Adora Ndu , Pharm.D., J.D., and Dr. Ravi Madduri Rao, M.D., Ph.D., as Me mbers of its Board of ...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN C...
Montrouge, France, May 5, 2021 DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, tod...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...
Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, toda...